*One Stock Before the Bell*

*Seagen Inc (NASDAQ: SGEN)*
$131.98 (+2.7% YTD)

Seagen develops and sells drugs that treat cancer and other related diseases. *Lymphoma drug Adcetris* garnered an *NCCN guideline update to category 1*, making it more likely to be chosen to treat patients. It also recently launched *breast cancer drug Tukysa in the EU following an accelerated approval by the FDA*. This is expected to result in *label expansion and drive profitability* for the foreseeable future.

*Q3 EPS and revenue* grew by 36.02% and 20.34% respectively, led by an 18.25% growth in *Adcetris*. SGEN has *beaten revenue estimates in 7 of the past 8 quarters*. It has a deep product pipeline that is rich in late-stage projects, with roughly *8 programs in phase 3 of clinical trials and 10 projects in phase 1*. The stock is attractively valued at a *blended forward Enterprise Value/Revenue ratio of 9.5x*, a *33% discount* to its 5Y average EV/REV.